

## PATENT COOPERATION TREATY

geel

From the  
INTERNATIONAL PRELIMINARY EXAMINING AUTHORITY

PCT

NOTIFICATION OF TRANSMITTAL OF  
THE INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT

(PCT Rule 71.1)

To:	
Altenburg, B.S.F. et al. OCTROOIBUREAU LOS EN STIGTER B.V. Weteringschans 96 NL-1017 XS Amsterdam PAYS-BAS	
App.	WO 800301
Imp.	17 NOV. 2004
Term.	26/01/2005 26/11

Date of mailing  
(day/month/year)

18.11.2004

Applicant's or agent's file reference  
WO 800301-AI/no

## IMPORTANT NOTIFICATION

International application No.  
PCT/NL 03/00545

International filing date (day/month/year)  
28.07.2003

Priority date (day/month/year)  
26.07.2002

Applicant  
MULTIGEN HOLDDING S.A. et al.

1. The applicant is hereby notified that this International Preliminary Examining Authority transmits herewith the international preliminary examination report and its annexes, if any, established on the international application.
2. A copy of the report and its annexes, if any, is being transmitted to the International Bureau for communication to all the elected Offices.
3. Where required by any of the elected Offices, the International Bureau will prepare an English translation of the report (but not of any annexes) and will transmit such translation to those Offices.

## 4. REMINDER

The applicant must enter the national phase before each elected Office by performing certain acts (filing translations and paying national fees) within 30 months from the priority date (or later in some Offices) (Article 39(1)) (see also the reminder sent by the International Bureau with Form PCT/IB/301).

Where a translation of the international application must be furnished to an elected Office, that translation must contain a translation of any annexes to the international preliminary examination report. It is the applicant's responsibility to prepare and furnish such translation directly to each elected Office concerned.

For further details on the applicable time limits and requirements of the elected Offices, see Volume II of the PCT Applicant's Guide.

The applicant's attention is drawn to Article 33(5), which provides that the criteria of novelty, inventive step and industrial applicability described in Article 33(2) to (4) merely serve the purposes of international preliminary examination and that "any Contracting State may apply additional or different criteria for the purposes of deciding whether, in that State, the claimed inventions is patentable or not" (see also Article 27(5)). Such additional criteria may relate, for example, to exemptions from patentability, requirements for enabling disclosure, clarity and support for the claims.

Name and mailing address of the international  
preliminary examining authority:



European Patent Office - P.B. 5818 Patentlaan 2  
NL-2280 HV Rijswijk - Pays Bas  
Tel. +31 70 340 - 2040 Tx: 31 661 epo nl  
Fax: +31 70 340 - 3016

Authorized Officer

Wallentin, M

Tel. +31 70 340-3991



**PATENT COOPERATION TREATY**  
**PCT**  
**INTERNATIONAL PRELIMINARY EXAMINATION REPORT**  
(PCT Article 36 and Rule 70)

REC'D 17 NOV 2004

WIPO

PCT



Applicant's or agent's file reference WO 800301-AI/no	<b>FOR FURTHER ACTION</b> See Notification of Transmittal of International Preliminary Examination Report (Form PCT/PEA/416)	
International application No. PCT/NL 03/00545	International filing date (day/month/year) 28.07.2003	Priority date (day/month/year) 26.07.2002
International Patent Classification (IPC) or both national classification and IPC C12Q1/68		
Applicant MULTIGEN HOLDDING S.A. et al.		

1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.
2. This REPORT consists of a total of 5 sheets, including this cover sheet.  
  
☒ This report is also accompanied by ANNEXES, i.e. sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).

These annexes consist of a total of 17 sheets.

3. This report contains indications relating to the following items:

- |      |                                     |  |
|------|-------------------------------------|--|
| I    | <input checked="" type="checkbox"/> | Basis of the opinion   |
| II   | <input type="checkbox"/>            | Priority   |
| III  | <input type="checkbox"/>            | Non-establishment of opinion with regard to novelty, inventive step and industrial applicability   |
| IV   | <input type="checkbox"/>            | Lack of unity of invention   |
| V    | <input checked="" type="checkbox"/> | Reasoned statement under Rule 66.2(a)(ii) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement |
| VI   | <input type="checkbox"/>            | Certain documents cited  |
| VII  | <input type="checkbox"/>            | Certain defects in the international application   |
| VIII | <input type="checkbox"/>            | Certain observations on the international application  |

Date of submission of the demand  23.02.2004	Date of completion of this report  18.11.2004
Name and mailing address of the International preliminary examining authority:   European Patent Office - P.B. 5818 Patentlaan 2 NL-2280 HV Rijswijk - Pays Bas Tel. +31 70 340 - 2040 Tx: 31 651 epo nl Fax: +31 70 340 - 3016	Authorized Officer  Gabriels, J  Telephone No. +31 70 340-4282  

**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT**

International application No. **PCT/NL 03/00545**

**I. Basis of the report**

1. With regard to the **elements** of the international application (*Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17)*):

**Description, Pages**

1-10 filed with telefax on 27.08.2004

**Claims, Numbers**

1-5 filed with telefax on 27.08.2004

**Drawings, Sheets**

1/5-5/5 filed with telefax on 27.08.2004

2. With regard to the **language**, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.

These elements were available or furnished to this Authority in the following language: , which is:

- ☐ the language of a translation furnished for the purposes of the international search (under Rule 23.1(b)).
- ☐ the language of publication of the international application (under Rule 48.3(b)).
- ☐ the language of a translation furnished for the purposes of international preliminary examination (under Rule 55.2 and/or 55.3).

3. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:

- ☐ contained in the international application in written form.
- ☐ filed together with the international application in computer readable form.
- ☐ furnished subsequently to this Authority in written form.
- ☐ furnished subsequently to this Authority in computer readable form.
- ☐ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
- ☐ The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.

4. The amendments have resulted in the cancellation of:

- ☐ the description, pages:
- ☐ the claims, Nos.:
- ☐ the drawings, sheets:

**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT**

International application No. **PCT/NL 03/00545**

5. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)).  
*(Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.)*

6. Additional observations, if necessary:

**V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability;  
citations and explanations supporting such statement**

1. Statement

Novelty (N)	Yes: Claims	1-5
	No: Claims	
Inventive step (IS)	Yes: Claims	
	No: Claims	1-5
Industrial applicability (IA)	Yes: Claims	1-5
	No: Claims	

2. Citations and explanations

**see separate sheet**

**V. Reasoned statement (Continuation)**

**2.1 CITATIONS**

Reference is made to the following documents:

- D1: EP-A-0 959 140 (BECTON DICKINSON CO) 24 November 1999 (1999-11-24)  
D2: EP-A-1 138 783 (ROCHE DIAGNOSTICS GMBH) 4 October 2001 (2001-10-04)

**2.2 NOVELTY (Art. 33(2) PCT)**

- 2.2.1 D1 discloses a method of determining a quantity of a nucleic acid sequence in a sample, comprising the steps of forming a plurality of standard samples (II) which each contain a known starting quantity of a nucleic acid control sequence (II') and a known starting quantity of a nucleic acid target sequence therein (I'); forming a test sample containing a known starting quantity of the nucleic acid control sequence and an unknown starting quantity of the nucleic acid target sequence (I); amplifying quantities of the nucleic acid control and target sequences in each of the standard samples and the test sample, during an amplification time interval; measuring indicia of the amplified quantities of the nucleic acid control and target sequences in each of the standard samples and the test sample; determining an amplification ratio from the measured indicia of the amplified quantities of the nucleic acid control and target sequences in the standard samples; and determining a magnitude of the starting quantity of the nucleic acid target sequence in the test sample from the amplification ratio and the measured indicia of the amplified quantities of the nucleic acid control and target sequences in the test sample. However, the different standard sequences do not reside on the same vector. Claims 1-5 are therefore novel.
- 2.2.2 D2 discloses a method for the quantification of a target nucleic acid in a sample comprising the following steps: a) determination of the amplification efficiency of the target nucleic acid under defined amplification conditions b) amplification of the target nucleic acid contained in the sample under the same defined reaction conditions c) measuring the amplification in real-time d) quantification of the original amount of target nucleic acid in the sample by correction of the original amount derived from step c) with the aid of the determined amplification efficiency.

However, the different standard sequences do not reside on the same vector. Claims 1-5 are therefore novel.

- 2.2.3 The present application does satisfy the criterion set forth in Article 33(2) PCT because the subject-matter of claims 1-5 is novel in respect of prior art as defined in the regulations (Rule 64(1)-(3) PCT).

**2.3 INVENTIVE STEP (Art. 33(3) PCT)**

- 2.3.1 Document D1 is considered to represent the most relevant state of the art (cf 2.2.1). The subject-matter of claim 1 differs in that the standard sequences do not reside on the same vector.
- 2.3.2 The problem to be solved by the subject matter of claim 1 may therefore be regarded as providing an internal control to obtain a more accurate measurement. The solution would be the use of standard sequences that reside on the same vector.
- 2.3.3 This solution ensures that the ratio is constant and exactly known. Since this aspect was not known or suggested in the prior art, arriving at the proposed solution would involve an inventive step.
- 2.3.4 The present application does therefore satisfy the criterion set forth in Article 33(3) PCT and the subject-matter of claims 1-6 does involve an inventive step (Rule 65(1)(2) PCT).



10/522405

WO 8001 Al/ho/co

DT05 Rec'd PCT/PTO 26 JAN 2005

Method of determining the copy number of a nucleotide sequence

The present invention relates to a method of determining the copy number of a nucleotide sequence I in a sample using an amplification technique, said method comprising the steps of

- 5 1) adding nucleotides, primers, polymerase and any further reagents, if any, required for the amplification technique used to the sample,
- 2) performing one or more amplification cycles to amplify the nucleotide sequence I for which the copy number has to be
- 10 determined;

where the sample contains a chromosomal second nucleotide sequence II, and

- a) the first nucleotide sequence I is amplified,
- b) the second nucleotide sequence II is amplified,
- 15 c) a third nucleotide sequence I' corresponding to the first nucleotide sequence I and present in a control sample is amplified at various dilutions, and
- d) a fourth nucleotide sequence II' corresponding to the second nucleotide sequence II and present in a control sample
- 20 is amplified at various dilutions,

where the ratio of the concentrations of nucleotide sequence I' and II' is known

- where the amplifications of the third and fourth nucleotide sequences I' and II' at various dilutions allows standard
- 25 curves SC<sub>i</sub> with i being I or II to be made, the concentrations of I and II are determined by using the respective standard curve SC<sub>i</sub>, and the relative concentrations allows the relative copy number CN of sequence I (versus nucleotide sequence II) to be determined using the formula

30

$$CN = \frac{[I]_{scr}}{[II]_{scr}}$$

EPO - DG 1

01. 09. 2004

(87)

35 where

AMENDED SHEET

CN is the relative copy number of I over II in the sample;  
[I]<sub>scr</sub> is the concentration of I determined using standard  
curve SC<sub>I</sub>; and

- 1) [II]<sub>scr</sub> is the concentration of II determined using stan-  
5      dard curve SC<sub>II</sub>.

Most eukaryotic diploid cells contain two copies of  
a single gene; one on each chromosome of a pair of chromo-  
somes. The chromosomes of a pair of chromosomes being derived  
from each parent, the genes may be different and, for exam-  
10      ple, one of them may result in a abnormal protein. Thus, the  
number of functional genes is not necessarily 2 in an eukary-  
ote, and can be 1 or even 0. While often genes are present in  
one copy per chromosome of a particular pair of chromosomes,  
some genes are present in multiple copies, for example in  
15      tandem repeat sequences. Another exception to the general  
rule of 2 copies per cel is mitochondrial DNA. A cell con-  
tains many mitochondria, the number being dependant on the  
type of cell. But even for a particular cell type, the number  
of mitochondria may vary. Typical numbers are between 100 and  
20      1000 mitochondria per cell, and each mitochondrion contains  
several copies of mitochondrial DNA. In addition, the typical  
copy number is not necessarily equal to larger than 2 per  
cell. Some nucleotide sequences are very rare among cells  
(despite being of one and the same subject, such as a human  
25      being). This is, for example, after gene rearrangement. This  
is, for example, the case with antibody producing cells (B-  
lymphocytes) or receptor-carrying T-lymphocytes. Of a large  
number of lymphocytes, only a few will contain a particular  
nucleotide sequence defining the variable region of a par-  
30      ticular antibody (or of the T-cell receptor), capable of rec-  
ognizing a particular antigen. In the art, a need exists to  
reliably determine the copy number of a nucleotide sequence,  
which may comprise the nucleotide sequence of a gene or part  
thereof. A method according to the preamble is known in the  
35      art.

A method according to the preamble is known dis-  
closed by Kwok et al in US 5,389,512.

The object of the present invention is to improve



this method for reliably determining the copy number of a nucleotide sequence even if it is present in extreme amounts, such as lots of copies per cell or only few copies per many cells. In addition, an object of the present invention is to  
5 provide a method which has reduced sensitivity to the efficiency with which DNA was extracted from the cells containing a nucleotide sequence I for which the copy number has to be determined.

To this end, the method according to the present invention is characterized in that  
10

at least one pair of amplification reactions chosen from i) a) and b), and ii) c) and d) is performed in a single container and monitored spectrophotometrically during amplification, and

15 the third nucleotide sequence I' and fourth nucleotide sequence II' resides on a single vector.

This allows for a more accurate measurement of relative or absolute copy numbers of nucleotide sequence I. Suitable spectrophotometrical methods are known in the art. More  
20 specifically, such methods rely on internal probes for real time measurements, for example real time PCR. Internal probes are known in the art, and are disclosed by, for example, Wiener et al (Anal. Biochem 270, pp. 41-49 (1999)). Measurements can be done either continuously, or after finishing an amplification cycle. While specific reference is made to standard  
25 curves, it goes without saying that this can be done using computational methods without an actual graph being made. Hence, in the present application the phrase "making a standard curve" involves any method using at least two reference  
30 points to determine a (relative) concentration. Generally, all amplifications will be performed substantially at the same time. By performing multiple amplifications in one container, the room for error is reduced. The method according to the invention is not only highly accurate, but it is also  
35 very efficient if performed for multiple samples. That is, for each nucleotide sequence I for which it is desired to determine the copy number, only a single standard curve SC<sub>II'</sub> has to be made. With respect to the term "corresponding" as

used in the present invention in conjunction with nucleotide sequences, this is intended to mean that the nucleotide sequences I and I' (and II and II'), or more specifically the nucleotide sequence of one and the complementary sequence of the other, are capable of hybridizing under stringent conditions. If the sequences I and I' (and II and II') do not have the same length, the shortest of the two is preferably at most 50% shorter, more preferably at most 30% shorter.

The third nucleotide sequence I' and fourth nucleotide sequence II' residing on the same vector allows their ratio to be constant and exactly known (for example 1:1). This allows for the most accurate measurements possible. It is possible to subject the vector containing both nucleotide sequence I' and II' to a digestion using one or more restriction enzymes, optionally followed by purification, to yield a linear molecule containing both both nucleotide sequence I' and II', and using this molecule for the amplifications required for the standard curves.

In the present application, a vector is understood to be any nucleotide sequence consisting of or containing the nucleotide sequence(s) to be amplified. When present on a vector capable of being replicated in vitro or in vivo, it is easy to obtain that particular nucleotide sequence in desired quantities. It is also very easy to determine the DNA concentration and hence the copy number of the nucleotide sequence per volume. A vector capable of replication or being replicated may be any such vector known in the art, such as a plasmid, a cosmid, a virus etc. If, according to a favourable embodiment, the third nucleotide sequence I' resides on first vector and the fourth nucleotide sequence II' resides on a second vector, the vectors can be used (or mixed) at any desired ratio to accommodate expected differences in copy number in the sample.

Douek et al (Nature 396, pp. 690-695 (1998)) describe a method for detecting the products of the rearrangements of T-cell receptors (TREC) using a semi-quantitative assay. For determining the amount of TREC in a given sample, a known amount of a DNA competitor are prepared. Then, an

amount of sample DNA containing the nucleotide sequence to be determined are added to the tube. A PCR amplification reaction is carried out in the presence of radiolabeled deoxynucleotide. Subsequently, the resulting amplification products are run on a gel to separate the sample DNA PCR product from the competitor DNA product. After autoradiography, the amount of nucleotide sequence to be determined is calculated using densitometric analysis from the ratio between a band of competitor DNA and a band of the sample DNA. The result is expressed as the number of copies of TREC per microgram total DNA. To achieve an acceptable accuracy, 4 tubes containing scalar amounts of competitor DNA are used, to which fixed amounts of sample DNA are added. The disadvantage of this method is that when DNA is extracted from cells, it must be assumed that this is all the DNA present in the cells. That is, it is assumed that no cell escaped lysis and all DNA present in the cells was extracted and isolated. This is not necessarily the case. Another disadvantage of this method is that it is sensitive to differences in amplification efficiency.

The European patent publication EP 0 959 140 discloses a method and apparatus for determining quantities of nucleic acid sequences in samples using standard curves and amplification ratio estimates. A plurality of standard samples each containing a known quantity of a nucleic acid control sequence, and a test sample containing a known quantity of the nucleic acid control sequence plus a nucleic acid sequence in an unknown concentration, are subjected to an amplification reaction. The concentration of the nucleic acid present in an unknown concentration in the test sample is determined.

The European patent publication EP 1 138 783 discloses a method for the quantification of a nucleic acid in a test sample, by determining the amplification efficiency under defined conditions, and performing the quantification of said nucleic acid under the same defined conditions, allowing correction of the concentration determined for said nucleic acid.

According to a preferred embodiment the absolute copy number is determined by multiplying the copy number CN by the absolute copy number of sequence II per cell.

For several nucleotide sequences II the number of  
5 copies of per cell is known. An example is, for example, the gene coding for heat shock protein 70, or Fas Ligand (CD178), which are known to be present with two copies per cell (i.e. the absolute copy number of hsp 70 = 2). Many nucleotide sequences of genes are very suitable because they generally are  
10 present in a known number of copies in every cell of the species from which the DNA is derived. The efficiency with which DNA material is extracted from the cells is not important (although, in case nucleotide sequence I is on a different molecule as nucleotide sequence II, it is important that they  
15 are extracted with the same efficiency). Hence, this embodiment allows determination of the absolute copynumber of the nucleotide sequence I per cell.

According to a preferred embodiment, at least two different third nucleotide sequences I' for measuring a corresponding number of different first nucleotide sequences I  
20 reside on a single vector.

In other words, a single vector, requiring its concentration to be determined only once, can carry multiple third nucleotide sequences I', which allows, for example, the  
25 copy numbers of many different genes to be determined.

Preferrably, the sequence of the first nucleotide sequence I is the same as the third nucleotide sequence I'.

This strongly reduces errors due to differences in amplification efficiencies between I and I'. Nevertheless,  
30 small differences in nucleotide sequence are generally allowed, although changes at locations where the probe used for detecting the concentration of the nucleotide sequence are best avoided. In other word, it is highly preferred if the probe is a perfect match for the sequence where it is in-  
35 tended to bind.

Similarly, it is preferred that the sequence of the second nucleotide sequence II is the same as the fourth nucleotide sequence II'.

While the present invention is described with reference to DNA, the present invention also applies to the determination of the number of RNA sequences present in a cell. Use can be made of methods known in the art to multiply RNA, for example by preparing cDNA. This application does not attempt to teach an interested layman how to become a person skilled in the art, for which reason the layman is referred to general text books and in particular to a proper university to learn the required techniques that a person skilled in the art knows how to apply these techniques to work the present invention.

The present invention will now be illustrated with reference to the drawings where

Fig. 1 represents a standard curve for an mtDNA sequence I' (circles) plus data for nucleotide sequence I (squares);

Fig. 2 represents a standard curve for a nuclear DNA sequence II' (circles) plus data for nucleotide sequence II (squares);

Fig. 3 represents a standard curve for a nuclear DNA sequence I' (circles) plus data for nucleotide sequence I (squares);

Fig. 4 represents a standard curve for a nuclear DNA sequence II' (FasL) (circles) plus data for nucleotide sequence II (squares); and

Fig. 5 shows the effect of age on the numbers of copies of TREC in peripheral lymphocytes (percentage of lymphocyte cells expressing TREC).

The method according to the invention will be illustrated using two Examples. The first relates to the quantitative analysis of mitochondrial DNA (mtDNA) and demonstrates the technique for determining multiple copies per cell. The second Example demonstrates the quantitative determination of a fractional copy number of a particular nucleotide sequence per cell.

### EXAMPLE 1

#### MATERIALS AND METHODS

##### Primers

The nucleotide sequence I (mtDNA) was a stretch



having a length of 102 nucleotides, and corresponds to part of the enzyme NADH dehydrogenase as coded for by mtDNA. Amplification of nucleotide sequence I was performed using a set of primers, each having a length of 21 nucleotides and synthesized using standard procedures. The sequences of both primers were checked to be unique for human mtDNA using Blast software, through the NCBI site at NIH (<http://www.ncbi.nlm.nih.gov/blast/>).

The nucleotide sequence II (nuclear DNA) serving as a reference, was a stretch having a length of 104 nucleotides and part of the FasL gene, which comes with two copies per human cell. Amplification of nucleotide sequence II was performed using a set of primers, each having a length of 21 and 24 nucleotides respectively.

#### Probes

To monitor the progress of amplification, a probe was used for nucleotide sequence I, the probe having a length of 23 nucleotides, having a FAM (carboxy fluorescein) fluorescent probe at the 5' end and a BlackHole Quencher1™ group at the 3' end. This probe, and all others in this application, was ordered commercially with MWG, Ebersberg, Germany. The sequence of the probe was checked to be unique for human mtDNA using Blast software, through the NCBI site as mentioned above.

The probe used for nucleotide II had a length of 22 nucleotides and contained TexasRed as the fluorescent label and a BlackHole Quencher2™ group at the 3' end (MWG).

#### DNA isolation

DNA was isolated from HL60, a promyelocytic leukaemia cell line, using a DNA isolation kit from Qiagen, Hilden, Germany according to the instructions of the manufacturer.

#### Control

A vector was constructed, using pGEM-11Z (Promega) containing the sequences I' and II' head to tail, using standard genetic engineering techniques, as all too familiar from Sambrook et al. (Molecular cloning. A lab manual. (1989)) in E. coli. The nucleotide sequences I' and II' were identical to their respective I and II counterparts, and present on the



vector in a highly defined 1:1 ratio.

The absolute concentration of the controls was done using limiting dilution assays (Sambrook).

#### Amplification

5        Amplification was performed using an iCycler Thermal cycler (BioRad, Hercules, CA, USA) using standard procedures. The amplification is performed in plates having 96 wells. This instrument allows monitoring of fluorescence in up to 4 different channels. In short, one cycle of denaturation (95  
10    °C for 6 min) was performed, followed by 45 cycles of amplification (94 °C for 30 s, 60 °C for 60 s). The amplification was performed in a mix that consisted of: Promega PCR buffer 1X (Promega, Madison, WI, USA), 3.0 mM MgCl<sub>2</sub>, 400 pmol of  
15    primers for mtDNA, 0.2 mM dNTP and 2 U of Taq polymerase (Promega). In accordance with the invention, the amplification for both nucleotide sequences I and II were performed in a single well, and the same is true for nucleotide sequences I' and II' (for determining the standard curves). Data were analysed using the software of the iCycler.

20        The standard curves were made by introducing a known number of copies of vector per well.

Amplification experiments were performed in triplicate.  
RESULTS

Fig. 1 shows the standard curve for nucleotide sequence  
25    I' and Fig. 2 shows the standard curve for the nucleotide sequence II' based on FasL. Note the excellent correlation coefficients of 0.995 and 0.996 respectively, indicating the excellent accuracy of the method according to the invention. Using these curves, the concentration of nucleotide sequences  
30    I and II (shown as squares in Figs. 1 and 2) were determined. As it is known that the nucleotide sequence for FasL (and more specifically for the probe for nucleotide II/II') is present with two copies per cell, the number of copies of nucleotide sequence I per cell is twice as high, i.e. 160.

35

#### EXAMPLE 2

Basically, the same method was used as described in Example 1, except that the nucleotide sequence I corresponded to part

of the sequence of the delta locus of the T-cell receptor. The method was used to determine the number of copies of TREC per cell, in particular peripheral lymphocytes in blood, in three age groups (healthy humans of 20, 60 or 100 years. The  
5 number of people were respectively 16 (10), 17 (10), and 21 (17), with the number of women between parentheses)

The standard curves for nucleotide sequence I' and II' are shown in fig. 3 and 4 respectively. The following correlation coefficients obtained were: 0.999 and 0.998.

10 Fig. 5 shows that the number of copies of TREC decreases with age (averages per age group shown as a horizontal line) from about 3.2 to 0.1 per 100 cells.

While particularly beneficial for the method according to the present invention in view of the fact that  
15 spectrophotometrical methods allow simultaneous detection of multiple labels, it is possible to perform an amplification reaction using any known amplification technique, where the third nucleotide sequence I' and fourth nucleotide sequence II' resides on a single vector and the amplifications of each  
20 of I' and II' are performed in separate containers, such as separate wells. The application covers this possibility as well. Such amplification techniques comprise, apart from the ones mentioned above, CP (Cycling Probe Reaction), bDNA (Branched DNA amplification), SSR (Self-Sustained Sequence  
25 Replication), SOA (Strand Displacement Amplification), QBR (Q-Beta Replicase), Re-AMP (Formerly RAMP), NASBA (Nucleic Acid Sequence Based Amplification), RCR (Repair Chain Reaction), LCR (Ligase Chain Reaction), TAS (Transcription Based Amplification System), and HCS (amplifies ribosomal RNA).

01.09.2004

CLAIMS

(87)

1. Method of determining the copy number of a nucleotide sequence I in a sample using an amplification technique, said method comprising the steps of
- 1) adding nucleotides, primers, polymerase and any further reagents, if any, required for the amplification technique used to the sample,
  - 2) performing one or more amplification cycles to amplify the nucleotide sequence I for which the copy number has to be determined;
- where the sample contains a chromosomal second nucleotide sequence II, and
- a) the first nucleotide sequence I is amplified,
  - b) the second nucleotide sequence II is amplified,
  - c) a third nucleotide sequence I' corresponding to the first nucleotide sequence I and present in a control sample is amplified at various dilutions, and
  - d) a fourth nucleotide sequence II' corresponding to the second nucleotide sequence II and present in a control sample is amplified at various dilutions,
- where the ratio of the concentrations of nucleotide sequence I' and II' is known
- where the amplifications of the third and fourth nucleotide sequences I' and II' at various dilutions allows standard curves  $SC_i$  with i being I or II to be made, the concentrations of I and II are determined by using the respective standard curve  $SC_i$ , and the relative concentrations allows the relative copy number CN of sequence I (versus nucleotide sequence II) to be determined using the formula

$$CN = \frac{[I]_{scr.}}{[II]_{scr.}}$$

where

- CN is the relative copy number of I over II in the sample;

[I]<sub>scr</sub> is the concentration of I determined using standard curve SC<sub>I</sub>; and

[II]<sub>scr</sub> is the concentration of II determined using standard curve SC<sub>II</sub>.

5 wherein

at least one pair of amplification reactions chosen from i) a) and b), and ii) c) and d) is performed in a single container and monitored spectrophotometrically during amplification, and

10 the third nucleotide sequence I' and fourth nucleotide sequence II' reside on a single vector.

2. Method according to claim 1, characterized in that the absolute copy number is determined by multiplying the copy number CN by the absolute copy number of sequence II  
15 per cell.

3. Method according to claim 1 or 2, characterized in that at least two and also more different third nucleotide sequences I' for measuring a corresponding number of different first nucleotide sequences I reside on a single vector.

20 4. Method according to any of the preceding claims, characterized in that the sequence of the first nucleotide sequence I is the same as the third nucleotide sequence I'.

5. Method according to any of the preceding claims, characterized in that the sequence of the second nucleotide  
25 sequence II is the same as the fourth nucleotide sequence II'.

EPO-DA 0.6522405

1/5

01. 09. 2004

(87)




FIG.1

10/522405

2/5

Correlation Coefficient: 0.996 Slope: -3.326 Intercept: 36.744  $Y = -3.326 X + 36.744$   
 PCR Efficiency: 99.8%

Unknowns  
 Standards




FIG.2

AMENDED SHEET



10/522405

3/5




FIG.3

10/522405

4/5




FIG.4

10/522405

5/5

Fig. 5

